Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus.
Arch Endocrinol Metab
; 66(6): 868-870, 2022 Nov 17.
Article
em En
| MEDLINE
| ID: mdl-36219203
ABSTRACT
"What's in a name? That which we call a rose / By any other name would smell as sweet" (Juliet, from Romeo and Juliet by William Shakespeare). Shakespeare's implication is that a name is nothing but a word and it therefore represents a convention with no intrinsic meaning. Whilst this may be relevant to romantic literature, disease names do have real meanings, and consequences, in medicine. Hence, there must be a very good rational for changing the name of a disease that has a centuries-old historical context. A working group of representatives from national and international endocrinology and endocrine pediatric societies now proposes changing the name of "diabetes insipidus" to "Arginine Vasopressin Deficiency (AVP-D)" for central etiologies, and "Arginine Vasopressin Resistance (AVP-R)" for nephrogenic etiologies This editorial provides both the historical context and the rational for this proposed name change.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Diabetes Insípido
/
Diabetes Mellitus
Tipo de estudo:
Guideline
Limite:
Child
/
Humans
Idioma:
En
Revista:
Arch Endocrinol Metab
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Japão